Sunitinib induced pyoderma gangrenosum-like ulcerations

European Journal of Medical Research

Volumn 16, Issue 11, 2011, Pages 491-494

  Akanay Diesel, S ^a   Hoff, N P ^a   Kurle S ^a   Haes, J ^a   Erhardt, A ^a   Haussinger D ^a   Schulte, K W ^a   Bölke, Edwin ^a   Matuschek, C ^a   Budach, W ^a   Gerber, P A ^a   Homey, B ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CREATININE; GEMCITABINE; HEMOGLOBIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PIPERACILLIN; SULBACTAM; SUNITINIB; TACROLIMUS; SORAFENIB;

ABDOMINAL RADIOGRAPHY; ADRENAL METASTASIS; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; COMORBIDITY; DEBRIDEMENT; DIAGNOSTIC TEST; DOPPLER ECHOGRAPHY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG METASTASIS; MALE; PYODERMA GANGRENOSUM; THROMBOCYTE COUNT; TREATMENT DURATION; ULCER HEALING; VEIN INSUFFICIENCY; CHEMOEMBOLIZATION; CLINICAL FEATURE; COMPRESSION THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN TISSUE; HYPOTHYROIDISM; MEDICAL HISTORY; SKIN ULCER;

AGED; ANTINEOPLASTIC AGENTS; ERYTHEMA; HUMANS; HYPERPIGMENTATION; HYPOPIGMENTATION; INDOLES; MALE; NEGATIVE-PRESSURE WOUND THERAPY; PYODERMA GANGRENOSUM; PYRROLES; ULCER;

EID: 82555193291     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D (2008) Pyoderma gangrenosum: another cutaneous side effect of sunitinib? Br J Dermatol. 2008 Jul;159(1):242-3 (Pubitemid 351874484)
2. Dean SM, Zirwas M (2010) A second case of Sunitinib-associated Pyoderma Gangrenosum. J Clin Aesthet Dermatol. 2010 August; 3(8):34-35
3. Hartmann JT, Kanz L (2008) Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 2008 Nov;144(11):1525-6.
4. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007 Sep;6(9):734-45 (Pubitemid 47338181)
5. Hoff NP, Bölke E, Matuschek C, Peiper M, Neumann NJ, Gerber PA (2010) Pyoderma gangraenosum. Wien Klin Wochenschr. 2010 Feb;122(3-4):75
6. Nadauld LD, Miller MB, Srinivas S (2010) Pyoderma Gangrenosum With the Use of Sunitinib. J Clin Oncol 2010, Vol 28
7. Nguyen S, Franklin M, Dudek AZ Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib. (2008) Transl Res. 2008 Apr
8. Nadauld LD, Miller MB, Sriniva S (2011) Pyoderma Gangrenosum With the Use of SunitinibJournal of Clinical Oncology, 2011, Vol 29
9. Neoh CY et al. Sweet's syndrome: a spectrum of unusual clinical presentations and associations. Br J Dermatol. 2007 Mar;156(3):480-5.
10. Gerber PA et al. Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors. Hautarzt 2010
11. Lübbe et al. Spongiosis induced by Erlotinib (Tarceva®). Dermatology 2008, 216:247-249
12. Marquardt C et al. Evaluation of the tissue toxicity of antiseptics by the hen's egg test on the chorioallantoic membrane (HETCAM). Eur J Med Res. 2010 May 18;15(5):204-9.
13. Harati A et al. Skin disorders in association with monoclonal gammopathies. Eur J Med Res. 2005 Mar 29;10(3):93-104. (Pubitemid 40514877)
14. Staehler M et al. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. Eur J Med Res. 2008 Nov 24;13(11):531-5.